Dalteparin SodiumFragmin
Recommended OtherRestrictedNot applicable line
Management of symptomatic venous thromboembolism in a patient with a solid tumour(s).
1
Submissions
2010–10
On the record
—
ICER range
Cost-min
Cost basis
Decisions on record
- Meeting Nov 2011 Recommended Blood thinner for use in haemodialysis no PSD
- Meeting Mar 2011 Recommended Anti-coagulant no PSD
- Meeting Nov 2010 Recommended Anti-blood clotting agent
- Meeting Dec 2001 Recommended An antithrombotic. no PSD
Access path
- TGA registered · Fragmin
- Nov 2010Recommended · restricted
vs enoxaparin
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis performed; no ICER calculated
The PBAC considered that the requested restriction might be ambiguous and not entirely aligned with the TGA registered indication. The requested PBS listing could be interpreted as being for the acute treatment of a VTE followed by continuing treatment of that patient to prevent recurrence; or it could be interpreted as to be used as prophylaxis in cancer patients with a past history of VTE. PBAC · 2010
Economic model disputed
Decision context
Populationpatients with a solid tumour(s) and symptomatic venous thromboembolism (VTE)
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2010 | Recommended · restricted | enoxaparin | — | RCT · Other |